MARC details
000 -LEADER |
fixed length control field |
06399cam a2201057Ia 4500 |
001 - CONTROL NUMBER |
control field |
ocn811139143 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
OCoLC |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20240729130944.0 |
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS--GENERAL INFORMATION |
fixed length control field |
m e d |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
fixed length control field |
cr cn||||m|||a |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
120926s2012 nyua foab 000 0 eng d |
040 ## - CATALOGING SOURCE |
Original cataloging agency |
CaBNvSL |
019 ## - |
-- |
843077259 |
-- |
858681730 |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
ISBN |
9781606504086 |
Qualifying information |
(electronic bk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
ISBN |
1606504088 |
Qualifying information |
(electronic bk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
ISBN |
9781606504222 |
Qualifying information |
(electronic bk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
ISBN |
1606504223 |
Qualifying information |
(electronic bk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
ISBN |
1283896060 |
Qualifying information |
(ebk) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
ISBN |
9781283896061 |
Qualifying information |
(ebk) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
Cancelled/invalid ISBN |
9780791860038 |
Qualifying information |
(print) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
Cancelled/invalid ISBN |
0791860035 |
Qualifying information |
(print) |
028 52 - PUBLISHER NUMBER |
Publisher number |
860038 |
Source |
asme |
035 ## - SYSTEM CONTROL NUMBER |
System control number |
501120 |
-- |
(N$T) |
035 ## - SYSTEM CONTROL NUMBER |
System control number |
(OCoLC)811139143 |
Canceled/invalid control number |
(OCoLC)843077259 |
-- |
(OCoLC)858681730 |
060 #4 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
Classification number |
2013 A-196 |
060 #4 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER |
Classification number |
WL 358 |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MED |
Subject category code subdivision |
108000 |
Source |
bisacsh |
049 ## - LOCAL HOLDINGS (OCLC) |
Holding library |
MAIN |
245 00 - TITLE STATEMENT |
Title |
Nanoparticles and brain tumor treatment |
Statement of responsibility, etc |
|
Medium |
[E-Book] |
246 1# - VARIANT TITLE |
Title |
Application of nanoparticles in brain tumor treatment |
260 ## - PUBLICATION INFORMATION |
Place of publication |
New York, N.Y. : |
Publisher |
ASME ; |
Place of publication |
[New York, N.Y.] (222 East 46th Street, New York, NY 10017) : |
Publisher |
Momentum Press, |
Date |
2012. |
300 ## - PHYSICAL DESCRIPTION |
Physical description |
1 online resource (viii, 99 pages) : |
Other physical details |
illustrations |
336 ## - CONTENT TYPE |
Content type term |
text |
Content type code |
txt |
Source |
rdacontent |
337 ## - MEDIA TYPE |
Media type term |
computer |
Media type code |
c |
Source |
rdamedia |
338 ## - CARRIER TYPE |
Carrier type term |
online resource |
Carrier type code |
cr |
Source |
rdacarrier |
490 1# - SERIES TITLE |
Series statement |
Biomedical and nanomedical technologies |
504 ## - BIBLIOGRAPHY, ETC. NOTE |
Bibliography, etc |
Includes bibliographical references (pages 81-99). |
505 0# - CONTENTS |
Contents |
1. Introduction. |
505 8# - CONTENTS |
Contents |
2. Glioma biology -- 2.1 Invasion and angiogenesis. |
505 8# - CONTENTS |
Contents |
3. Blood-brain barrier -- 3.1 Blood-brain barrier physiology -- 3.2 Blood-brain barrier transport systems. |
505 8# - CONTENTS |
Contents |
4. Nanomedicine and nanotechnology -- 4.1 Nanoparticle drug delivery -- 4.1.1 Nanoparticle distribution -- 4.1.2 Nanoparticle functionalization -- 4.1.3 Nanoparticle targeting -- 4.2 Nanomedicine and cancer -- 4.3 Nanomedicine and toxicity. |
505 8# - CONTENTS |
Contents |
5. Nanoparticle technologies -- 5.1 Polymeric and polymer-drug conjugate nanoparticles -- 5.2 Micelle nanoparticles -- 5.3 Liposomes -- 5.4 Gold and silver nanoparticles -- 5.5 Metal oxide -- 5.6 Magnetic nanoparticles -- 5.7 Carbon nanotubes -- 5.8 Fullerenes -- 5.9 Peptides nanoparticles -- 5.10 Silica nanoparticles -- 5.11 Quantum dots -- 5.12 Dendrimers. |
505 8# - CONTENTS |
Contents |
6. Nanomedicine applications in brain tumors -- 6.1 Brain tumor drug targeting -- 6.1.1 Systemic approaches -- 6.1.2 Physiological approaches -- 6.1.2.1 Receptor-mediated transcytosis -- 6.1.2.2 Adsorptive-mediated transcytosis -- 6.1.2.3 Efflux pump inhibition -- 6.1.2.4 Cell-mediated drug transport -- 6.1.3 Direct CNS approaches -- 6.1.3.1 Intracerebral routes -- 6.1.4 Drug modifications and prodrugs. |
505 8# - CONTENTS |
Contents |
7. Experimental studies. |
505 8# - CONTENTS |
Contents |
8. Conclusions -- References. |
520 3# - ABSTRACT |
Abstract |
Despite progresses in surgery, radiotherapy, and in chemotherapy, an effective curative treatment of gliomas does not yet exist. Mortality is still close to 100% and the average survival of patients with GBM is less than 1 year. The efficacy of current anti-cancer strategies in brain tumors is limited by the lack of specific therapies against malignant cells. Besides, the delivery of the drugs to brain tumors is limited by the presence of the blood brain barrier. The oncogenesis of gliomas is characterized by several biological processes and genetic alterations, involved in the neoplastic transformation. The modulation of gene expression to more levels, such as DNA, mRNA, proteins and transduction signal pathways, may be the most effective modality to down-regulate or silence some specific gene functions. Gliomas are characterized by extensive microvascular proliferation and a higher degree of vasculature. In malignant gliomas targeted therapies efficacy is low. In this complex field, it seems to be very important to improve specific selective drugs delivery systems. Drugs, antisense oligonucleotides, small interference RNAs, engineered monoclonal antibodies and other therapeutic molecules may diffuse into CNS overcoming the BBB. Nanotechnology could be used both to improve the treatment efficacy and to reduce the adverse side effects. |
590 ## - LOCAL NOTE (RLIN) |
Local note |
WorldCat record variable field(s) change: 650 |
650 #0 - SUBJECT HEADINGS |
Subject term |
Nanomedicine. |
650 #0 - SUBJECT HEADINGS |
Subject term |
Nanoparticles. |
650 #0 - SUBJECT HEADINGS |
Subject term |
Brain |
General subdivision |
Tumors |
-- |
Treatment. |
650 #0 - SUBJECT HEADINGS |
Subject term |
Nanotechnology. |
650 #2 - SUBJECT HEADINGS |
Subject term |
Brain Neoplasms |
General subdivision |
therapy |
650 #2 - SUBJECT HEADINGS |
Subject term |
Nanomedicine |
650 #2 - SUBJECT HEADINGS |
Subject term |
Nanoparticles |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Nanomedicine |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Nanotechnology |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Nanoparticles |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Nanoparticles in Brain Tumor Treatment |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Nanoparticle Drug Delivery |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Nanoparticle Targeting |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Blood-Brain Barrier |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Glioma |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Astrocytoma |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Glioblastoma |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Brain Tumor |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Glioma Treatment |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Brain Tumor Drug Targeting |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Angiogenesis |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Polymeric |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Nanoparticles and Brain Tumors |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Carbon Nanotubes and Brain Tumors |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Fullerenes and Brain Tumors |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Silica Nanoparticles and Brain Tumors |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Micelle Nanoparticles and Brain Tumors |
653 ## - INDEX TERM--UNCONTROLLED |
Uncontrolled term |
Liposome and Brain Tumors |
700 1# - ADDED PERSONAL NAME |
Added personal author |
Caruso, Gerardo. |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
Uniform title |
Biomedical & nanomedical technologies. |
856 ## - ONLINE RESOURCE |
Uniform Resource Identifier |
<a href="#gotoholdings">#gotoholdings</a> |
Link text |
Access resource |
942 ## - ADDED ENTRY ELEMENTS (KOHA) |
Suppress in OPAC |
Do not Suppress in OPAC |
588 0# - SOURCE OF DESCRIPTION NOTE |
Source of description note |
Online resource; title from PDF title page (Momentum Press, viewed April 12, 2013). |
938 ## - |
-- |
Coutts Information Services |
-- |
COUT |
-- |
24444258 |
938 ## - |
-- |
ebrary |
-- |
EBRY |
-- |
ebr10605115 |
938 ## - |
-- |
EBSCOhost |
-- |
EBSC |
-- |
501120 |
938 ## - |
-- |
ProQuest MyiLibrary Digital eBook Collection |
-- |
IDEB |
-- |
cis24444258 |
938 ## - |
-- |
Momentum Press |
-- |
NYMP |
-- |
9781606504222 |
938 ## - |
-- |
YBP Library Services |
-- |
YANK |
-- |
9728798 |
938 ## - |
-- |
YBP Library Services |
-- |
YANK |
-- |
11669335 |
994 ## - |
-- |
92 |
-- |
N$T |